On Friday, Deutsche Bank (ETR:DBKGn) updated its outlook on Redcare Pharmacy NV (RDC:GR) shares, increasing the price target to €182.00 from the previous €178.00. The firm sustained its Buy rating on the stock. The adjustment reflects confidence in Redcare's operational performance and its potential in the e-prescription market in Germany.
Redcare has been performing robustly, and the analyst from Deutsche Bank anticipates that this momentum will be bolstered by the company's expansion into the e-prescription (eRx) business.
The analyst noted that the risks associated with the eRx business have significantly diminished, with no remaining doubts about the rollout or access to the eRx system. This development positions Redcare to capitalize on the German e-prescription market, which is valued at over €50 billion.
The recommendation from Deutsche Bank suggests that the recent dip in Redcare's share price presents an opportunity for investors to increase their holdings. The firm's positive stance on Redcare's investment case is reiterated, highlighting the company's promising trajectory.
The report emphasizes that the improved price target is a result of a valuation rollover. Deutsche Bank's maintained Buy rating and revised price target signal a favorable outlook for Redcare Pharmacy NV, as the company is poised to benefit from the expanding e-prescription market and its strong operational performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.